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Celecoxib enhances anticancer effect 
of cisplatin and induces anoikis  
in osteosarcoma via PI3K/Akt pathway
Bing Liu1, Shigui Yan1*, Liyan Qu2,3 and Jian Zhu1
Abstract 
Background: COX-2, an inducible enzyme, is associated with inflammatory diseases and carcinogenesis. Overexpres-
sion of COX-2 occurs in many human malignancies, including osteosarcoma. COX-2 positivity is form 67 to 92% in 
osteosarcoma, and COX-2 expresses 141-fold more in cancer stem cell spheres than daughter adherent cells. In our 
study, we have reported that celecoxib, a cyclooxygenase-2 inhibitor, induces apoptosis in human osteosarcoma cell 
line MG-63 via down-regulation of PI3K/Akt. It has been confirmed that celecoxib enhances apoptosis and cytotoxic 
effect of cisplatin, although the mechanism remains unclear.
Methods: We have attempted to identify the anti-proliferation of celecoxib, a selective COX-2 inhibitor, and the 
combination of celecoxib and cisplatin in MG-63 cells, and to explore the potential molecular mechanisms involved. 
MG-63 cells were treated with the combination of celecoxib and cisplatin or either agent alone for 48 h in serum-
supplemented medium.
Results: MDR1, MRP1, BCRP and Trkb, E-cadherin, β-catenin were significantly downregulated in cells treated with 
the combination of celecoxib and cisplatin, and decreased β-catenin level was found in cells with wortmannin, a 
specific PI3K inhibitor.
Conclusion: Therefore, celecoxib enhances anticancer effect of cisplatin and induces anoikis in osteosarcoma, which 
may be PI3K/Akt-dependent, and MDR and β-catenin-related. PI3K may be at the center of the celecoxib effects, 
which play an essential role in the regulation of MDR and anoikis.
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Background
The cyclooxygenase (COX) isoenzymes, known as 
prostaglandin (PG) rate-limiting synthase. COX-2, an 
inducible enzyme, is associated with inflammatory dis-
eases and carcinogenesis, which is suspected to pro-
mote angiogenesis and tissue invasion of tumours [1, 2] 
and the overexpression of COX-2 has been mentioned 
in connection with resistance to apoptosis [3, 4]. Non-
steroidal anti-inflammatory drugs (NSAIDs) have been 
shown to induce apoptosis as well as potentiate the effect 
of chemotherapeutic agents including cisplatin [5, 6]. 
Celecoxib is a NSAIDs that is a specific inhibitor of COX-
2. Although the precise mechanisms for the chemopre-
ventive effects of celecoxib are not yet known, the ability 
of the inhibition of cell proliferation, and induction of 
apoptosis has been well-known [7, 8]. COX-2 is also 
involved in drug resistance and poor prognosis of tumor 
[9].
Osteosarcoma is the most common primary bone 
tumor in children and young adults, which has been 
reported to express COX-2 constitutively [10–12]. 
COX-2 positivity is form 67 to 92% in osteosarcoma 
[13, 14], and COX-2 expresses 141-fold more in can-
cer stem cell (CSC) spheres than daughter adherent 
cells [15]. Therefore, we can exert the drug to affect the 
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over-expressed genes and achieve the therapies of human 
malignancies.
In our study, we have reported that celecoxib, a 
cyclooxygenase-2 inhibitor, induces apoptosis in human 
osteosarcoma cell line MG-63 via down-regulation of 
PI3K/Akt [16]. It has been confirmed that celecoxib 
enhances the apoptosis induction and cytotoxic effect 
of cisplatin, although the mechanism remains unclear. 
COX-inhibitors may sensitize cancer cells to chemother-
apeutic drugs via inhibiting P-gp, MRP1 and BCRP, and 
enhance the effect of anticancer drugs. PI3K/Akt plays 
an essential role in the cell/extracellar matrix (ECM) and 
cell/cell adhesion. Lack of the correct adhesion, the adhe-
sion-dependent signals will be interrupted, which will 
result in adhesion-related apoptosis: anoikis. We have 
attempted to identify the anti-proliferation of celecoxib, 
a selective COX-2 inhibitor, and the combination of 
celecoxib and cisplatin in MG-63 cells, and to explore the 
potential molecular mechanisms involved.
Methods
Reagents
Celecoxib was generously provided by Pharmacia Cor. 
(New York, NY, USA) and dissolved in DMSO (40 mM) 
as a stock solution in 4  °C. Cisplatin was purchased 
from Qilu Pharmaceutical Co., Ltd. (ShanDong prov-
ince, China) and dissolved in normal saline (2  mg/ml) 
as a stock solution in 4 °C. Celecoxib and cisplatin were 
added at various concentrations to cells in 10% fetal 
bovine serum (FBS)-containing DMEM. The final DMSO 
concentration never exceeded 0.1% (v/v) after addition 
to medium. Mouse monoclonal antibodies specific for 
PI3K p110 (sc-8010), β-catenin (sc-7963); rabbit poly-
clonal antibodies specific for E-cadherin (sc-7870), Trkb 
(sc-8316), β-actin (sc-1616R);secondary antibodies were 
obtained from Santa Cruz Biotechnology, Inc.(Santa 
Cruz, CA, USA) were purchased from Calbiochem (San 
Diego, CA, USA).
Cells and cell culture
The human OS cell line MG-63 used in this study were 
obtained from American Type Culture Collection 
(Manassas, VA), and the U2OS cells were purchased 
from the ATCC (HTB-96; Rockville, Maryland, USA), 
HOS (CRL-1547TM, ATCC) was obtained from Cell 
Bank of Shanghai Institute of Biochemistry & Cell Biol-
ogy, Chinese Academy of Sciences (Shanghai, China). 
MG-63 Cells were grown in DMEM medium (Gibco Life 
Sciences) supplemented with 10% (v/v) heat activated 
fetal bovine serum (Gibco Life Sciences) in a humidified 
atmosphere of 5% CO2 at 37 °C. U2OS cells were grown 
in RPMI1640 medium and HOS cells were grown in 
Eagle’s Minimum Essential medium containing supple-
ments as above.
Real time quantitative RT‑PCR analysis
RNA was isolated from the cells using Trizol (Invitrogen) 
according to the manufacturer’s instructions. cDNA was 
generated from total denatured RNA (2 µg) by using 1 µl 
oligo(dT)18 primer, 25 units RNase inhibitor, 2 µl dNTPs 
(10 mM), and a Moloney Murine Leukemia Virus reverse 
transcriptase cDNA synthesis kit (Promega, Madison, 
WI, USA). Quantitative real-time PCR was performed 
using Applied Biosystems 7500 Real-Time PCR Sys-
tem and SYBR® Premix Ex Taq™ kit (Perfect Real Time) 
(TaKaRa, Dalian, China). Human 18s rRNA was used as 
internal control. The Cycle threshold (CT) values for each 
gene were corrected using the mean CT value. Real-time 
PCR data were quantified using the ΔCT method with 
the formula: n =  100 ×  2−(ΔCT targeted gene −  ΔCT 18s rRNA). 
Targeted genes were amplified by real time PCR with 
the following primers: 18s rRNA forward: 5′GACTC 
AACACGGGAAACCTCAC3′ and reverse: 5′CCAG 
ACAAATCGCTCCACCAAC3′; Human BCRP, for-
ward 5′GCAGCAGGTCAGAGTGTGGTTT3′, reverse 
5′GCTGCAAAGCCGTAAATCCATA3′; Human MRP1 
forward: 5′CGCTGAGTTCCTGCGTACCTAT′ and 
reverse: 5′CCATTCTCCATTTGCTTTGCTT3′, Human 
MDR1 forward: 5′CCGTGGGGCAAGTCAGTTCAT3′ 
and reverse: 5′CCTTCCAATGTGTTCGGCATTAG3′.
Western blot analysis
After the exposure for 48  h, floating and adherent cells 
were harvested and rinsed twice with cold PBS and lysed 
in lysis buffer [50  mM Tris (pH 7.4), 400  mM NaCl, 
50 mM NaF, 30 mM sodium PPi, 1 mM sodium pyroven-
didate, 1% SDS, and 0.5% NP40]. Protein concentrations 
were determined with bicinchoninic acid protein assay 
(Pierce, Rockford, IL, USA). Cellular proteins, at a con-
centration of 40 µg, were fractionated on 12% SDS-PAGE 
(Invitrogen/Novex, Carlsbad, CA, USA). Proteins were 
then transferred to a polyvinylidene difluoride mem-
brane (Immobilon-P; Millipore, Bedford, MA, USA). The 
membrane was blocked with 5% nonfat milk in TBST and 
incubated overnight with antibody at 4  °C. After wash-
ing three times with TBST, the membrane was incubated 
at room temperature for 1  h with horseradish peroxi-
dase-conjugated secondary antibody diluted with TBST 
(1:1000). The detected protein signals were visualized by 
an enhanced chemiluminescence reaction system (Amer-
sham, Arlington Heights, IL, USA), and the signal was 
visualized with X-ray film (Hyperfilm; Amersham).
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Electrophoretic mobility shift assay (EMSA) for β‑catenin 
activation
Cells were treated with celecoxib (50 and 100  µmol/l), 
cisplatin (10  µg/ml), and the combined administration 
for 48  h. Nuclear proteins were prepared using nuclear 
and cytoplasmic protein extraction reagents according to 
the manufacturer’s protocols (Pierce, Rockford, IL, USA). 
The crude nuclear pellet was suspended in 200 µL buffer 
B (20  mmol/l HEPES pH 7.9; 25% glycerol, 1.5  mmol/l 
MgCl2; 420  mmol/l NaCl, 0.5  mmol/l DTT; 0.2  mmol/l 
EDTA; 0.5 mmol/l PMSF; and 4 µmol/l leupeptidin) and 
incubated on ice for 30 min. The suspension was centri-
fuged at 16,000×g at 4  °C for 30  min. The supernatant 
was collected as nuclear proteins. A non-radioactive 
EMSA was performed using an EMSA kit (Pierce, Rock-
ford, IL, USA) according to the manufacturer’s instruc-
tions. Nuclear protein (4 µg) extracted from the cells or 
tissues was incubated with biotinylated oligonucleotides 
containing the β-catenin site for 30  min at room tem-
perature. The samples were separated in a nondenaturing 
polyacrylamide gel (6%, with 2.5% glycerol) and blot-
ted on a Biodyne B (0.45  mm) positively charged nylon 
membrane (Pall Schweiz AG, Basel, Switzerland). The 
biotin was labeled with alkaline phosphatase-conjugated 
streptavidin and alkaline phosphatase was detected with 
Enhanced Chemiluminescense detection system (Santa 
Cruz, CA, USA).
Statistical analysis
The entire experiment was done in triplicate and the data 
are presented as mean ± SD. The statistical significance 
of differences was determined by Student’s two-tailed 
t test in two groups and one-way ANOVA in multiple 
groups. P  <  0.05 was considered statistically significant. 
All data were analyzed with SPSS 16.0 software.
Results
Down‑regulation of MDR1, MRP1 and BCRP correlated 
with increased apoptosis
We have reported that celecoxib caused G1 phase arrest 
and significantly inhibited cell growth, as well as poten-
tiating cisplatin-induced apoptosis. MG-63 cells were 
exposed to celecoxib (50 and 100  µmol/l), cisplatin 
(10  µg/ml), and the combined administration for 48  h, 
and the apoptosis rate was 1.39, 4.06, 5.98, 5.93, 6.66, 
37.15%, respectively, which may be result from COX-
2-related drug resistance. The activity of COX-2-PGE2-
Prostaglandin E Receptors signal pathway can upregulate 
the expression of all three ABC transporters, MDR1/P-gp 
(multidrug resistance/P-glycoprotein), MRP1 (multidrug 
resistance protein 1) and BCRP (breast cancer resistance 
protein), which encode efflux pumps, play important 
roles in the development of multidrug resistance [17]. 
The potential mechanism of MDR1, MRP1 and BCRP 
in celecoxib and/or cisplatin treated cells were therefore 
investigated. Figure  1 shows that the downregulation of 
MDR1, MRP1 and BCRP mRNA expression was found 
in cells treated with celecoxib (50 and 100  µmol/l), cis-
platin (10  µg/ml), and the combined administration for 
48  h. Moreover, significant downregulation of MDR1, 
MRP1 and BCRP was detected in cells treated with the 
combination of celecoxib (100  µmol/l) and cisplatin 
compared with either agent alone, with apoptosis being 
strongly increased. However, no potentiation of celecoxib 
(50 µmol/l) and cisplatin was found. The results of treated 
MG-63 cells were similar in Western blot analysis (Fig. 2).
Modulation of Trkb, E‑cadherin and β‑catenin expression 
in MG‑63 cells treated with celecoxib and cisplatin
We have reported that celecoxib, a cyclooxygenase-2 
inhibitor, induces apoptosis in human osteosarcoma cell 
line MG-63 via down-regulation of PI3K/Akt. PI3K/
Akt plays an essential role in the cell/extracellar matrix 
(ECM) and cell/cell adhesion. Lack of the correct adhe-
sion, the adhesion-dependent signals will be interrupted, 
which will result in adhesion-related apoptosis: anoikis 
[18]. Trkb, E-cadherin and β-catenin play an important 
role in the cell/cell adhesion [19]. In this study we found 
the down-regulations of E-cadherin and β-catenin in 
MG-63, U2OS and HOS cells, as shown in Fig. 3. Signifi-
cant down-regulations of Trkb, E-cadherin and β-catenin 
activation were observed in MG-63 cells treated with cis-
platin and celecoxib (100 µmol/l).
The effect of celecoxib and cisplatin on nuclear expression 
of β‑catenin
As show in Fig.  4, constitutively active nuclear expres-
sion of β-catenin binding activity was observed in nuclear 
extracts from MG-63, U2OS and HOS cells. In all cells, 
compared with untreated control, both celecoxib and 
cisplatin treatment obviously decreased β-catenin bind-
ing activity, meanwhile, significant down-regulation of 
β-catenin binding activity was displayed in MG-63 and 
U2OS cells. These results suggest that celecoxib not 
only down-regulates β-catenin binding activity but also 
sensitizes cisplatin effect, which may be responsible for 
enhanced inhibition of cell viability and inducing apopto-
sis by combination treatment.
PI3K inhibition by wortmannin causing to the decease 
of pAkt and β‑catenin
To investigate the role of PI3K in cells treated with 
celecoxib, we gave wortmannin (1  mmol/l) to cells for 
48  h, but did not see downregulation of total PI3K and 
Akt, although downregulation of pAkt (Thr308) and 
β-catenin was detected (Fig. 5).
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Fig. 1 Regulation of MDR1, MRP1 and BCRP expression. RT-PCR analysis MDR1, MRP1 and BCRP expression of MG-63 cells untreated or treated with 
celecoxib (50, 100 µmol/l), cisplatin (10 µg/ml), and the combination for 48 h. Significant down-regulation of MDR1, MRP1 and BCRP expression was 
observed in cells treated with cisplatin
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A hypothetical model for PI3K and COX‑2 pathway 
interaction
Celecoxib down-regulates the expression of PI3K/Akt, 
which plays an essential role in the regulation of MDR1, 
MRP1, BCRP and Trkb, E-cadherin, β-catenin, eventually 
causing anoikis. PI3K negatively regulates the expression 
of COX-2. It demonstrate that celecoxib enhances the 
anoikis induction and cytotoxic effect of cisplatin (Fig. 6).
Discussion
COX-2 is an inducible enzyme and associated with 
inflammatory diseases and carcinogenesis, which is sus-
pected to promote angiogenesis and tissue invasion 
of tumors and resistance to apoptosis. COX-2 is also 
involved in drug resistance and poor prognosis of tumor. 
In the present study, it reveals that celecoxib and cispl-
atin inhibit cell growth via induction of apoptosis, and 
celecoxib potentiate the growth inhibition of cisplatin 
[5, 6]. In our study, a significant reduction in cell viability 
and apoptosis in MG-63 cells treated with the combina-
tion of celecoxib and cisplatin as compared with either 
celecoxib or cisplatin alone was observed.
Recently, a causal link between COX-2 and MDR-1 
gene expression, implicated in cancer chemoresistance, 
has been demonstrated. Patel et al. [20] showed that the 
overexpression of COX-2 leads to increased P-gp expres-
sion and activity, and this effect is dependent on COX-2 
activity. In addition, COX-2 inhibitor was able to block 
the COX-2-mediated increase in MDR1 expression and 
activity [20]. It has revealed that the expression of COX-2 
and the downstream enzyme involved in PGE2 biosyn-
thesis, mPGES1, was correlated with P-gp and Bcl-xL 
[21]. COX-2 overexpression induced increased MRP-1 
expression resulting in chemoresistance to cisplatin 
[22]. Strong positive correlation between the expres-
sion of COX-2 and MDR1/P-gp was also observed in 
hepatocellular carcinoma, breast cancer and ovarian 
cancer [23–25]. In addition, COX-2 may be a factor that 
can regulate the expression of all three ABC transporters: 
MDR1/P-gp, MRP1 and BCRP [26].
Nonsteroidal anti-inflammatory drugs (NSAIDs) have 
been shown to induce apoptosis as well as potentiate 
the effect of chemotherapeutic agents including cispl-
atin. Celecoxib is a NSAIDs which is a specific inhibitor 
of COX-2. NSAIDs and COX-2 selective inhibitors have 
been demonstrated to overcome MDR in many cancers. 
It has been suggested that COX-inhibitors may sensi-
tize cancer cells to chemotherapeutic drugs via inhibit-
ing P-gp, MRP1 and BCRP, and enhance the effect of 
anticancer drugs [27]. In imatinib-resistant K562 cells, 
celecoxib can inhibit COX-2 and down-regulate MDR-1 
expression through Akt/p-Akt signaling pathway [27]. 
Akt/protein kinase B (PKB) belongs to the downstream 
molecules of PI3K, which plays an important role in 
PGE2-EP4 pathway, as shown above. COX-2 inhibitors 
are known to inhibit the PI3K/Akt pathway [28]. We have 
confirmed that celecoxib induces apoptosis in human 
osteosarcoma cell line MG-63 via down-regulation of 
PI3K/Akt, as well as potentiates the effect of cisplatin 
[16]. In breast cancer, COX-2 inhibitors can also inhibit 
P-gp expression and function [29]. Celecoxib down-regu-
lated the expression of MRP1 protein in human lung can-
cer, which was accompanied by increased accumulation 
and enhanced cytotoxicity of doxorubicin [30]. Ko et al. 
[31] demonstrated that celecoxib reverses BCRP- and 
MRP1-related drug resistance via the down-regulation 
of MRP1 and BCRP mRNA in squamous cell carcinoma. 
Therefore, COX-2 may play an important role in upregu-
lation the expression of MDR1/P-gp, MRP1 and BCRP 
via the COX-2-PGE2-EP4-PI3K pathway. In addition, 
COX-2 inhibitors can reverse the effects of COX-2. And 
the mechanisms of COX-2 inhibitors regulate the tran-
scription of the MDR still do further research.
PI3K/Akt plays a central role in regulation of adhesion 
[32]. In cell/cell attachment, β-catenin serves as a com-
ponent of the cytoskeleton [19]. β-catenin associates with 
the intracellular tail of the intercellular adhesion mole-
cule E-cadherin [33]. Through this association, β-catenin 
plays an important role in strong cell–cell adhesion as it 
links E-cadherin to the actin cytoskeleton through the 
protein α-catenin [34]. Another function of β-catenin is 
that maintaining cell-to-cell adhesion and mediating the 
Wnt/β-catenin signal transduction pathway, which plays 
pivotal roles in embryogenesis and in malignant transfor-
mation of cells [35]. It has reported that E-cadherin is lost 
from cell–cell contacts before the execution of apoptosis 
[36]. Activation of PI3K/Akt signaling has been shown to 
mediate survival signals triggered by the engagement of 
E-cadherin [37] and other classical cadherins [38, 39].
Fig. 2 Regulation of MDR1, MRP1 and BCRP expression. Western blot 
analysis MDR1, MRP1 and BCRP expression of MG-63 cells untreated 
or treated with celecoxib (50, 100 µmol/l), cisplatin (10 µg/ml), and 
the combination for 48 h. Significant down-regulation of MDR1, MRP1 
and BCRP expression was observed in cells treated with cisplatin
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Fig. 3 The down-regulations of Trkb, E-cadherin and β-catenin activation were detected in MG-63 cells treated with celecoxib (50, 100 µmol/l), cis-
platin (10 µg/ml), and the combination for 48 h. Significant down-regulations of Trkb, E-cadherin and β-catenin activation were observed in MG-63 
cells treated with cisplatin and celecoxib (100 µmol/l). However, the potentialization of celecoxib (50 µmol/l) and cisplatin was not demonstrated. 
β-actin was used as an equal loading control
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The present report suggests that β-catenin may also 
lie downstream of integrins. Several integrin-stimu-
lated signaling pathways might lead to the induction of 
β-catenin signaling. One possible connection between 
integrins and β-catenin is the integrin-activated, antia-
poptotic kinase PKB/Akt. PKB is known to inhibit the 
activity of glycogen synthase kinase 3-β, a serine kinase 
that functions directly to reduce β-catenin protein and 
signaling [40, 41]. It is possible that the result of these two 
inhibitory interactions is that activation of PKB by inte-
grin signaling functions to positively activate β-catenin 
signaling. TrkB is a receptor tyrosine kinase that has 
brain-derived neurotrophic factor (BDNF) as one of its 
primary ligands. It has been established that BDNF bind-
ing to TrkB receptors results in a highly specific receptor 
autophosphorylation [42] and in turn activates the PI3K/
Akt pathway [43].
In conclusion, MDR1, MRP1, BCRP and Trkb, E-cad-
herin, β-catenin were significantly downregulated in 
cells treated with the combination of celecoxib and cis-
platin, and decreased β-catenin level was found in cells 
with wortmannin, a specific PI3K inhibitor. Therefore, 
celecoxib enhances anticancer effect of cisplatin and 
induces anoikis in osteosarcoma, which may be PI3K/
Akt-dependent, and MDR and β-catenin-related. PI3K 
may be at the center of the celecoxib effects, which play 
an essential role in the regulation of MDR and anoikis.
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